Ricardo Blanco Alonso-rekin lankidetzan egindako argitalpenak (30)

2024

  1. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  2. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

    Seminars in Arthritis and Rheumatism, Vol. 68

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

    RMD Open, Vol. 8, Núm. 2

  3. Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy

    Clinical and experimental rheumatology, Vol. 40, Núm. 5, pp. 988-992

2020

  1. Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis

    Clinical and experimental rheumatology, Vol. 38, Núm. 6, pp. 1201-1205

  2. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662

  3. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis

    Reumatologia Clinica, Vol. 16, Núm. 4, pp. 272-281

  4. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: Data from the RELESSER Registry

    Rheumatology (United Kingdom), Vol. 59, Núm. 8, pp. 2043-2051

2019

  1. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis

    Clinical and experimental rheumatology, Vol. 37, Núm. 3, pp. 465-473

  2. Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 6, pp. 1025-1029

2018

  1. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 1, pp. 22-27

2017

  1. Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study

    Arthritis Care and Research, Vol. 69, Núm. 1, pp. 38-45

  2. Juvenile- and adult-onset systemic lupus erythematosus: A comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 6, pp. 1047-1055

2016

  1. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation

    Ocular Immunology and Inflammation, Vol. 24, Núm. 2, pp. 167-172

  2. Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, pp. 40-47

  3. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry

    Rheumatology (United Kingdom), Vol. 55, Núm. 7, pp. 1243-1250

2015

  1. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus

    Lupus, Vol. 24, Núm. 7, pp. 720-729

  2. Cardiovascular events in systemic lupus erythematosus: A Nationwide Study in Spain from the RELESSER Registry

    Medicine (United States), Vol. 94, Núm. 29

  3. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the spanish rheumatology society lupus registry (RELESSER) with emphasis on complete versus incomplete lupus differences

    Medicine (United States), Vol. 94, Núm. 1, pp. e267